Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)
Sponsor: NHS Greater Glasgow and Clyde
Summary
Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging. This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.
Official title: Biomarkers in SCOTland CardiomyopatHy Registry
Key Details
Gender
All
Age Range
10 Years - Any
Study Type
OBSERVATIONAL
Enrollment
750
Start Date
2024-06-26
Completion Date
2027-03-19
Last Updated
2024-07-03
Healthy Volunteers
No
Interventions
Plasma biomarker levels
This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy. Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines.
Locations (1)
Queen Elizabeth University Hospital
Glasgow, United Kingdom